during the rapidly evolving subject of oncology investigate, correct and economical mutation screening is important for developing focused therapies. The KRAS providers Platform plays a pivotal function During this landscape by offering extensive methods for KRAS mutation profiling and Investigation. KRAS mutations, present in about 95% of RAS-conn